Menu
The only validated SAA clinically available for the detection of pathogenic misfolded a-synuclein.
Supports early diagnosis, stratification and management of Alzheimer’s disease, Lewy body dementia and atypical Parkinson’s disease.
This website is intended for the informational purposes of healthcare professionals.
How the SAAmplify-ɑSYN Test helps improve diagnostic accuracy for various types of Parkinson's.
How the SAAmplify-ɑSYN Test can improve the diagnostic challenges of Lewy body dementia.
How the SAAmplify-ɑSYN Test helps differentiate the Alzheimer's variant: AD with Lewy bodies.
How the SAAmplify-ɑSYN Test helps physicians differentiate MSA from Parkinson's disease.
How the SAAmplify-ɑSYN Test helps detect Minimal Cognitive Impairment with Lewy bodies early.
Details on the SAAmplify-ɑSYN Test performance characteristics.
A pioneer of prion detection science, Amprion innovates biomarker testing to accurately detect misfolded proteins associated with brain diseases.
After decades of research, Amprion is thrilled to roll out its impactful discoveries from the lab to the world.
We get a lot of questions from healthcare providers. That happens when you’re challenging the status quo to reimagine medicine. And we have answers—backed up by empirical evidence.
Reach out to learn more about how Amprion tests can support your practice and patients.
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.
Effective September 9, 2024, SYNTap will be
And stay tuned for the SAAmplify family of panels, coming soon!
